{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:00:35Z","timestamp":1787014835740,"version":"build-2736575974"},"reference-count":11,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T00:00:00Z","timestamp":1269820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:p>\n                    Recent research provided important insights into the development of atrial fibrillation (AF)\u2010maintaining substrate and suggested targeting of the underlying molecular mechanisms, \u2018upstream\u2019 of the electrical aspects of AF, as a novel strategy for AF treatment (\u2018upstream\u2019 therapy). Upstream therapies for AF include drugs targeting the renin\u2010angiotensin II\u2010aldosterone system (angiotensin converting enzyme inhibitors and AT\n                    <jats:sub>1<\/jats:sub>\n                    receptor antagonists and aldosterone antagonists), statins, steroids and \u03c9\u20103 fatty acids (fish oil). Aldosterone causes volume retention, cardiac hypertrophy and fibrosis, and systemic inflammation and coagulation that promote AF development and its complications and blockade of aldosterone receptors with spironolactone or eplerenone suppresses inducible AF. Although the clinical impact of spironolactone treatment requires validation in randomized clinical trials in AF patients, further understanding of the molecular mechanisms by which aldosterone causes atrial remodelling is likely to lead to development of novel therapeutic approaches to AF.\n                  <\/jats:p>\n                  <jats:p>\n                    This article is a commentary on Zhao\n                    <jats:italic>et al.<\/jats:italic>\n                    , pp. 1584\u20131594 of this issue. To view this paper visit\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/dx.doi.org\/10.1111\/j.1476-5381.2009.00551.x\">http:\/\/dx.doi.org\/10.1111\/j.1476\u20105381.2009.00551.x<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1111\/j.1476-5381.2010.00675.x","type":"journal-article","created":{"date-parts":[[2010,3,29]],"date-time":"2010-03-29T08:52:31Z","timestamp":1269852751000},"page":"1581-1583","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Aldosterone\u2010receptor antagonism as a potential therapeutic option for atrial fibrillation"],"prefix":"10.1111","volume":"159","author":[{"given":"Uwe","family":"Lendeckel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,29]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.23.2678"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00611-2"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01905-1"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.805804"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.196576"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi478"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2007.07.008"},{"key":"e_1_2_5_9_1","first-page":"816","article-title":"Expression of mineralocorticoid receptor and 11\u2010beta\u2010hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases","volume":"87","author":"Pei DA","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2006.00372.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00097-7"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00551.x"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2010.00675.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2010.00675.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:25:20Z","timestamp":1697405120000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2010.00675.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,29]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1476-5381.2010.00675.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00675.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,29]]},"assertion":[{"value":"2010-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}